NIH research reveals new insights about how “bad” cholesterol works in the body, findings that could pave the way for more personalized treatments for cardiovascular disease.
Summary: Researchers at the National Institutes of Health (NIH) have made an advancement in understanding how low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, accumulates in the body. Using advanced imaging techniques, the team uncovered how the main structural protein of LDL binds to its receptor, initiating the process that clears LDL from the bloodstream. The study also identified genetic mutations that disrupt this process, leading to high LDL levels and increasing the risk of heart disease. These findings could lead to more effective, personalized treatments for lowering LDL, especially for people with genetic conditions like familial hypercholesterolemia, and improve therapies for those on statins.
Key Takeaways:
- Breakthrough in LDL Cholesterol Research: NIH scientists discovered how LDL cholesterol binds to its receptor, a process that plays a key role in clearing LDL from the blood.
- Implications for Heart Disease: The findings could help develop targeted therapies for genetic conditions, such as familial hypercholesterolemia, and improve treatments for those with high cholesterol.
- Potential to Enhance Statin Effectiveness: By understanding the exact binding mechanism of LDL, researchers may design new drugs that more effectively lower LDL cholesterol in the blood.
Scientists at the National Institutes of Health (NIH) have advanced understanding of how low-density lipoprotein cholesterol (LDL-C), often referred to as “bad” cholesterol, accumulates in the body.
The researchers demonstrated how the main structural protein of LDL binds to its receptor—– a process that starts the clearing of LDL from the blood—and what happens when that process gets impaired.
The findings, published in Nature, further the understanding of how LDL contributes to heart disease, the world’s leading cause of death, and could open the door to personalizing LDL-lowering treatments like statins to make them even more effective.
“LDL is one of the main drivers of cardiovascular disease which kills one person every 33 seconds, so if you want to understand your enemy, you want to know what it looks like,” says Alan Remaley, MD, PhD, co-senior author on the study who runs the Lipoprotein Metabolism Laboratory at NIH’s National Heart, Lung, and Blood Institute, in a release.
[RELATED: Eating a Dozen Eggs Weekly Doesn’t Harm Cholesterol Levels, Study Finds]
Until now scientists have been unable to visualize the structure of LDL, specifically what happens when it links up with its receptor, a protein known as LDLR. Typically, when LDL binds to LDLR, the process of clearing LDL from the blood begins. But genetic mutations can prevent that work, causing LDL to build up in the blood and get deposited into the arteries as plaque, which can lead to atherosclerosis, a precursor for heart disease.
Advanced Technology Reveals New Insights
In the new study, the researchers were able to use high-end technology to get a view of what’s happening at a critical stage of that process and see LDL in a new light.
“LDL is enormous and varies in size, making it very complex,” says Joseph Marcotrigiano, PhD, chief of the Structural Virology Section in the Laboratory of Infectious Diseases at NIH’s National Institute of Allergy and Infectious Diseases and co-senior author on the study, in a release. “No one’s ever gotten to the resolution we have. We could see so much detail and start to tease apart how it works in the body.”
Using advanced imaging technique called cryo-electron microscopy, the researchers were able to see the entirety of the structural protein of LDL when it bound to LDLR. Then, with artificial intelligence-driven protein prediction software, they were able to model the structure and locate the known genetic mutations that result in increased LDL. The developers of the software, who were not involved in the study, were recently awarded the 2024 Nobel Prize in Chemistry.
The researchers found that many of the mutations that mapped to the location where LDL and LDLR connected, were associated with an inherited condition called familial hypercholesterolemia (FH). FH is marked by defects in how the body uptakes LDL into its cells, and people with it have extremely high levels of LDL and can have heart attacks at a very young age. They found that FH-associated variants tended to cluster in particular regions on LDL.
Researchers say the study findings could open new avenues to develop targeted therapies aimed at correcting these kinds of dysfunctional interactions caused by mutations. But, as importantly, the researchers say, they could also help people who do not have genetic mutations, but who have high cholesterol and are on statins, which lower LDL by increasing LDLR in cells. By knowing precisely where and how LDLR binds to LDL, the researchers say they may now be able to target those connection points to design new drugs for lowering LDL from the blood.
ID 81806086 © Marek Uliasz | Dreamstime.com
